**Supplementary Tables**

**Supplementary Table 1.** Clinical characteristics and disease progression in women in the Flatiron Health database who received adjuvant therapy

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Women who received AT,**  **n (%)** | **ECOG at initial AT,  n (%) [1]** | | | | | | | **Progression after AT,  n (%) [2]** | | |
| **Evidence of evaluation** | | **ECOG performance status  (among women with documented score)** | | | | |
| No | Yes | 0 | 1 | 2 | 3 | 4 | Women without documented progression | Women who progressed | Median time from AT to progression, months (range) |
| **HR+/HER2– eBC** | | | | | | | | | | | |
| Overall (n=328) | 304  (92.7) | 146 (48.0) | 158  (52.0) | 91 (57.6) | 55 (34.8) | 11  (7.0) | 1 (0.6) | 0  (0.0) | 279  (91.8) | 25  (8.2) | 7.4  (0.1−44.1) |
| pCR; yes (n=20) | 15  (75.0) | 6  (40.0) | 9  (60.0) | 5  (55.6) | 3 (33.3) | 1  (11.1) | 0  (0.0) | 0  (0.0) | 15  (100.0) | 0  (0.0) | - |
| pCR; no (n=259) | 241  (93.1) | 105  (43.6) | 136  (56.4) | 78  (57.4) | 47  (34.6) | 10  (7.4) | 1  (0.7) | 0  (0.0) | 217  (90.0) | 24  (10.0) | 6.9 (0.1−44.1) |
| **eTNBC** | | | | | | | | | | | |
| Overall (n=168) | 46  (27.4) | 12  (26.1) | 34  (73.9) | 21  (61.8) | 11 (32.4) | 2 (5.9) | 0  (0.0) | 0  (0.0) | 34  (73.9) | 12  (26.1) | 9.7  (0.2−41.0) |
| pCR; yes (n=60) | 6  (10.0) | 1  (16.7) | 5  (83.3) | 3  (60.0) | 2 (40.0) | 0  (0.0) | 0  (0.0) | 0  (0.0) | 5  (83.3) | 1  (16.7) | 0.2  (0.2−0.2) |
| pCR; no (n=105) | 38  (36.2) | 10  (26.3) | 28  (73.7) | 17  (60.7) | 9 (32.1) | 2  (7.1) | 0  (0.0) | 0  (0.0) | 27  (71.1) | 11  (28.9) | 10.1 (0.8−41.0) |

[1] Defined as the closest value prior to the start date of the AT. [2] Defined as (distant metastatic date – last adjuvant therapy end date). ECOG scoring system: 0- fully active; 1- restricted in physically strenuous activity but ambulatory; 2- ambulatory and capable of self-care; 3- capable of only limited self-care; 4- completely disabled. AT, adjuvant therapy; eBC, early breast cancer; ECOG, Eastern Cooperative Oncology Group; eTNBC, early triple-negative breast cancer; HER2, human epidermal growth factor receptor-2; HR, hormone receptor; pCR, pathologic complete response.

**Supplementary Table 2.** Treatment patterns in the Flatiron Health database who received adjuvant therapy

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Women who received AT**  **[1]** | **Time from initial eBC diagnosis to first AT**  **[2]** | **Duration of AT**  **[3]** | **AT agents,**  **n (%) [4]** | | | |
| n,  (%) | Median time,  Days (range) | Median duration,  Days (range) | Anastrozole | Letrozole | Tamoxifen | Capecitabine |
| **HR+/HER2– eBC** | | | | | | | |
| Overall (n=328) | 304  (92.7) | 206  (1−1396) | 915  (13−3096) | 64  (21.1) | 33  (10.9) | 32  (10.5) | 1  (0.3) |
| pCR; yes (n=20) | 15  (75.0) | 229  (136−308) | 837  (43−2554) | 2  (13.3) | 2  (13.3) | 3  (20.0) | 0  (0.0) |
| pCR; no (n=259) | 241  (93.1) | 225  (23−1396) | 954  (29−3096) | 58  (24.1) | 30  (12.4) | 25  (10.4) | 1  (0.4) |
| **eTNBC** | | | | | | | |
| Overall (n=168) | 46  (27.4) | 235  (73−637) | 151  (14−2797) | 2  (4.3) | 0  (0.0) | 2  (4.3) | 16  (34.8) |
| pCR; yes (n=60) | 6  (10.0) | 262  (140−637) | 57  (42−2797) | 1  (16.7) | 0  (0.0) | 0  (0.0) | 0  (0.0) |
| pCR; no (n=105) | 38  (36.2) | 235  (73−424) | 156  (14−1834) | 1  (2.6) | 0  (0.0) | 2  (5.3) | 16  (42.1) |

[1] Defined as (first adjuvant therapy start date-initial eBC diagnosis date). If initial adjuvant therapy start date was prior to initial eBC diagnosis date, duration was set as 0. [2] Defined as time between the first adjuvant therapy start date and last adjuvant therapy end date +1. [3] Women can be represented in more than one therapy class. [4] The four most common treatment sequences are shown. AT, adjuvant therapy; eBC, early breast cancer; eTNBC, early triple-negative breast cancer; HER2, human epidermal growth factor receptor-2; HR, hormone receptor; pCR, pathologic complete response; SERD, selective estrogen receptor degrader.